Skip to content

Study · Measured the body's own peptide · 1977

3 results

Intractable diarrhea in a boy with vasoactive intestinal peptide-producing ganglioneuroblastoma.

Jansen-Goemans A, Engelhardt J

Pediatrics1 May 1977Cited by 20 (Europe PMC)

PMID854377 (opens in a new tab)DOI10.1542/peds.59.5.710 (opens in a new tab)PepBankPUB-00854377
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelCase report or seriesOther

    In a boy with a VIP-producing ganglioneuroblastoma, the body's own VIP blood levels were elevated before surgery.

    In plain wordsIn a boy with a VIP-producing tumour, the body's own VIP blood levels were high before surgery.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseBlood VIP level before surgery
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    The ganglioneuroblastoma in this instance contained the enterohormone vasoactive intestinal peptide (VIP); blood levels of this peptide were elevated preoperatively.
    1 context sentence
    Summary · context
    A 1-year-old boy had intractable diarrhea and symptoms of the watery-diarrhea-hypokalemia-achlorhydria (WDHA) syndrome, a well-known entity in adults.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelCase report or seriesOther

    In a boy with a VIP-producing ganglioneuroblastoma, the body's own VIP level returned to normal after tumor resection.

    In plain wordsIn a boy with a VIP-producing tumour, the body's own VIP level returned to normal after the tumour was removed.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseBlood VIP level after tumor resection
    Study

    n = 1

    Comparator
    Preoperative level
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    After tumor resection, the VIP level returned to normal, and the diarrhea ceased on the day of the operation.
    1 context sentence
    Summary · context
    A 1-year-old boy had intractable diarrhea and symptoms of the watery-diarrhea-hypokalemia-achlorhydria (WDHA) syndrome, a well-known entity in adults.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelCase report or seriesOther

    In a boy with a VIP-producing ganglioneuroblastoma, intractable diarrhea ceased on the day of tumor resection, when the body's own VIP level fell.

    In plain wordsIn a boy with a VIP-producing tumour, diarrhea stopped on the day the tumour was removed, when the body's own VIP levels fell.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseDiarrhea after tumor resection
    Study

    n = 1

    Comparator
    Preoperative state
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Resection of a ganglioneuroblastoma situated in the neck caused prompt relief of symptoms.
    2 context sentences
    Summary · context
    the diarrhea ceased on the day of the operation.
    Summary · context
    A 1-year-old boy had intractable diarrhea and symptoms of the watery-diarrhea-hypokalemia-achlorhydria (WDHA) syndrome, a well-known entity in adults.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.